Semax

Description

Semax (MEHFPGP) is a neuropeptide derived from the sequence Met–His–Phe–Pro–Gly–Pro-Arg, closely related to the adrenocorticotropic hormone (ACTH) segment (4-10). Renowned for its prolonged neurotropic activity, this peptide primarily addresses disorders related to cerebral circulation dysfunction and various intellectual-amnestic issues within the central nervous system.

Uses and Indications:
Semax is employed for a range of conditions, including but not limited to:
– Anxiety management
– Memory enhancement
– Cerebral ischemic events or stroke recovery
– Treatment of ADHD (Attention Deficit Hyperactivity Disorder)
– Withdrawal symptoms from opioids
– Chronic neurological diseases, including Amyotrophic Lateral Sclerosis (ALS), Parkinson’s disease, and Alzheimer’s disease.

Additionally, Semax displays antithrombotic and fibrinolytic effects, contributing to the prevention of cardiovascular disorders and enhancing the immune system.

Mechanism of Action:
Semax functions as an antagonist of the M4 melanocortin receptor, thereby inhibiting its effects while simultaneously augmenting the production of brain-derived neurotrophic factor (BDNF), crucial for long-term memory and neural development. Clinical findings indicate that Semax significantly elevates BDNF expression and TrkB receptor signaling within the hippocampus. It rapidly activates the serotonergic and dopaminergic systems, enhancing mood regulation and cognitive function.

Individuals treated with Semax over a period of 10 to 14 days exhibited reductions in anxiety and depressive behaviors, highlighting its potential as an anti-anxiety and antidepressant agent. Additionally, research has shown a diminished behavioral response to chronic stress, further suggesting efficacy in managing symptoms of depression and ADHD.

Cognitive Enhancements:
Semax is recognized for its nootropic effects, promoting:
– Increased selective attention
– Improved memory retention
– Enhanced learning abilities
– Greater adaptability and stability of brain function.

It is particularly valued among nootropic enthusiasts due to its gentle yet effective enhancement of mental functions without stimulation, positively influencing memory, associative thinking, cognitive processes, and overall stress management.

Dosage:
The suggested dosage of Semax ranges from 3 to 70 mcg/kg of body weight, tailored to the specific goals of treatment. however, it is important to note that due to regulatory and licensing constraints, no specific guidance or recommendations on its use or research practices can be provided.

In summary, Semax stands out as a promising agent in the realm of cognitive enhancement and therapeutic interventions for various neurological and psychological conditions, thanks to its multifaceted benefits and supportive research findings.

1. Dolotov, OV, et al. Semax, an ACTH(4–10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 2006.

2. Eremin, KO, et al. Semax, an analog of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neuroscience Research, 2006.

3. Kravkov, NP, et al. Effects of heptapeptide semax on dopaminergic and serotoninergic systems of the rat brain. Pharmacology, Biochemistry and Behavior, 2009.

4. Ashmarin, IP, et al. Semax, an analogue of adrenocorticotropin (4-7), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Neuropsychopharmacology, 2006.

5. Manchenko, DM, et al. Effect of semax on the activity and emotional behavior of rats. Bulletin of Experimental Biology and Medicine, 2013.

6. Medvedev, VE, et al. Effects of Semax and Its C-Terminal Fragment Pro-Gly-Pro on the Morphofunctional State of Rat Hippocampus during Experimental Alzheimer’s Disease. Journal of Alzheimer’s Disease, 2018.

7. Sobolevsky, T, et al. Effects of semax and its C-terminal fragment on calcium homeostasis of neurons and their survival under conditions of glutamate toxicity. Biochemical Pharmacology, 2002.

Favor notare che mentre ci sono molte ricerche fatte sugli effetti di Semax, la FDA non ha approvato l’uso di Semax al di fuori di studi